Back to Journals » Biologics: Targets and Therapy » Volume 6

Monoclonal antibodies and Fc fragments for treating solid tumors

Authors Eisenbeis, Grau S

Received 10 October 2011

Accepted for publication 16 November 2011

Published 5 January 2012 Volume 2012:6 Pages 13—20

DOI https://doi.org/10.2147/BTT.S19955

Review by Single-blind

Peer reviewer comments 4


Andrea M Eisenbeis, Stefan J Grau
Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany

Abstract: Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number of molecular markers have facilitated the use of monoclonal antibodies and Fc fragments in various fields in medicine. In this context, a rapidly growing number of these substances have also emerged in the field of oncology. This review will summarize the currently approved monoclonal antibodies used for the treatment of solid tumors with a focus on their clinical application, biological background, and currently ongoing trials.

Keywords: targeted therapy, monoclonal antibodies, cancer, biological therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]